Nature Medicine
@natmed.nature.com
Nature Medicine is a research journal devoted to publishing the latest advances in translational and clinical research for scientists and physicians.
www.nature.com/nm
www.nature.com/nm
Pinned
⚡Our November issue is out! Featuring trials of #CARTcells for #LUPUS, an #ADC for #lungcancer, cardiac #genetherapy, an #ebola #vaccine, discovery of microbial elements in #braintumors, #liquidbiopsies, #newbornscreening, News, Reviews, & more.
https://www.nature.com/nm/volumes/31/issues/11
https://www.nature.com/nm/volumes/31/issues/11
A landmark clinical trial of gene therapy infusion for hemophilia B revealed surprising findings—reshaping the future of genetic medicine.
Read the full Turning Point essay in Nature Medicine: https://ow.ly/RVST50XvVs0
#GeneTherapy #HemophiliaB #NatureMedicine
Read the full Turning Point essay in Nature Medicine: https://ow.ly/RVST50XvVs0
#GeneTherapy #HemophiliaB #NatureMedicine
Turning genes into medicines - Nature Medicine
The first clinical trial of a gene therapy infusion for hemophilia B revealed unexpected findings.
ow.ly
November 21, 2025 at 5:17 PM
A landmark clinical trial of gene therapy infusion for hemophilia B revealed surprising findings—reshaping the future of genetic medicine.
Read the full Turning Point essay in Nature Medicine: https://ow.ly/RVST50XvVs0
#GeneTherapy #HemophiliaB #NatureMedicine
Read the full Turning Point essay in Nature Medicine: https://ow.ly/RVST50XvVs0
#GeneTherapy #HemophiliaB #NatureMedicine
Women, children & adolescents bear the brunt of climate impacts — from preterm births to malnutrition.
In Nature Medicine, Rajat Khosla, Helen Clark & co-authors outline actionable strategies for climate resilience & health equity.
Free to access 👉 www.nature.com/articles/d41...
#COP30 #HealthForAll
In Nature Medicine, Rajat Khosla, Helen Clark & co-authors outline actionable strategies for climate resilience & health equity.
Free to access 👉 www.nature.com/articles/d41...
#COP30 #HealthForAll
November 20, 2025 at 5:27 PM
Women, children & adolescents bear the brunt of climate impacts — from preterm births to malnutrition.
In Nature Medicine, Rajat Khosla, Helen Clark & co-authors outline actionable strategies for climate resilience & health equity.
Free to access 👉 www.nature.com/articles/d41...
#COP30 #HealthForAll
In Nature Medicine, Rajat Khosla, Helen Clark & co-authors outline actionable strategies for climate resilience & health equity.
Free to access 👉 www.nature.com/articles/d41...
#COP30 #HealthForAll
⚡Our November issue is out! Featuring trials of #CARTcells for #LUPUS, an #ADC for #lungcancer, cardiac #genetherapy, an #ebola #vaccine, discovery of microbial elements in #braintumors, #liquidbiopsies, #newbornscreening, News, Reviews, & more.
https://www.nature.com/nm/volumes/31/issues/11
https://www.nature.com/nm/volumes/31/issues/11
November 19, 2025 at 4:33 PM
⚡Our November issue is out! Featuring trials of #CARTcells for #LUPUS, an #ADC for #lungcancer, cardiac #genetherapy, an #ebola #vaccine, discovery of microbial elements in #braintumors, #liquidbiopsies, #newbornscreening, News, Reviews, & more.
https://www.nature.com/nm/volumes/31/issues/11
https://www.nature.com/nm/volumes/31/issues/11
A combination of high resolution spatial imaging, spatial proteomics and transcriptional data reveals sparse and heterogeneous bacterial signals in gliomas and brain metastases. @gmorad.bsky.social https://www.nature.com/articles/s41591-025-03957-4
November 19, 2025 at 1:15 PM
A combination of high resolution spatial imaging, spatial proteomics and transcriptional data reveals sparse and heterogeneous bacterial signals in gliomas and brain metastases. @gmorad.bsky.social https://www.nature.com/articles/s41591-025-03957-4
Pretrained using 335,645 whole-slide images, a foundation model is developed to provide representations for slide- and patient-level tasks. It is capable of performing clinical tasks even in data-scarce scenarios, without further fine-tuning. https://www.nature.com/articles/s41591-025-03982-3
November 18, 2025 at 3:15 PM
Pretrained using 335,645 whole-slide images, a foundation model is developed to provide representations for slide- and patient-level tasks. It is capable of performing clinical tasks even in data-scarce scenarios, without further fine-tuning. https://www.nature.com/articles/s41591-025-03982-3
Cities are often at the forefront of creative policy opportunities; our latest Perspective from Ana Diez-Roux & Usama Bilal outlines a policy-focused #urbanhealth research agenda that emphasizes #populationhealth and environmental sustainability
https://www.nature.com/articles/s41591-025-04031-9
https://www.nature.com/articles/s41591-025-04031-9
Advancing equitable and sustainable urban health - Nature Medicine
Cities are often at the forefront of creative thinking on policy opportunities; this Perspective outlines an agenda for urban health research that promotes a virtuous cycle by which population health and environmental sustainability support and reinforce each other.
www.nature.com
November 18, 2025 at 12:00 PM
Cities are often at the forefront of creative policy opportunities; our latest Perspective from Ana Diez-Roux & Usama Bilal outlines a policy-focused #urbanhealth research agenda that emphasizes #populationhealth and environmental sustainability
https://www.nature.com/articles/s41591-025-04031-9
https://www.nature.com/articles/s41591-025-04031-9
A study meticulously uncovers bacterial elements in malignant brain tumors,
providing a blueprint for studying #microbial signals in other low-biomass tissues. News & Views from Allyson Byrd & Jayanth Jawahar Benaroya Research Institute
https://www.nature.com/articles/s41591-025-03980-5
providing a blueprint for studying #microbial signals in other low-biomass tissues. News & Views from Allyson Byrd & Jayanth Jawahar Benaroya Research Institute
https://www.nature.com/articles/s41591-025-03980-5
Building a blueprint for intra-tumoral microbial studies - Nature Medicine
A study meticulously uncovers bacterial elements within malignant brain tumors; the approach opens avenues for understanding brain cancer biology and provides a blueprint for studying microbial signals in other low-biomass tissues.
www.nature.com
November 17, 2025 at 3:02 PM
A study meticulously uncovers bacterial elements in malignant brain tumors,
providing a blueprint for studying #microbial signals in other low-biomass tissues. News & Views from Allyson Byrd & Jayanth Jawahar Benaroya Research Institute
https://www.nature.com/articles/s41591-025-03980-5
providing a blueprint for studying #microbial signals in other low-biomass tissues. News & Views from Allyson Byrd & Jayanth Jawahar Benaroya Research Institute
https://www.nature.com/articles/s41591-025-03980-5
New data shows that as patients approach the end stages of #cancer, tumors exploit the body’s largest highways — infiltrating major vessels and unleashing clusters of tumor cells into the circulation.
News & Views from Anirban Maitra and colleagues.
https://www.nature.com/articles/s41591-025-04052-4
News & Views from Anirban Maitra and colleagues.
https://www.nature.com/articles/s41591-025-04052-4
Understanding end-of-life cancer biology - Nature Medicine
A new study reveals that as patients approach the end stages of their disease, cancer may exploit the body’s largest highways — infiltrating major blood vessels and unleashing clusters of tumor cells into the circulation.
www.nature.com
November 17, 2025 at 1:30 PM
New data shows that as patients approach the end stages of #cancer, tumors exploit the body’s largest highways — infiltrating major vessels and unleashing clusters of tumor cells into the circulation.
News & Views from Anirban Maitra and colleagues.
https://www.nature.com/articles/s41591-025-04052-4
News & Views from Anirban Maitra and colleagues.
https://www.nature.com/articles/s41591-025-04052-4
In cognitively normal older adults at risk for Alzheimer’s dementia, physical inactivity was associated with faster tau protein buildup and cognitive decline https://www.nature.com/articles/s41591-025-03955-6 @WendyYau01 @HarvardAging @MGHNeurology
November 17, 2025 at 12:20 PM
In cognitively normal older adults at risk for Alzheimer’s dementia, physical inactivity was associated with faster tau protein buildup and cognitive decline https://www.nature.com/articles/s41591-025-03955-6 @WendyYau01 @HarvardAging @MGHNeurology
⭐Research highlight: #Adjuvant #atezolizumab improved survival outcomes in patients with muscle-invasive #bladdercancer who had no radiographic disease but had detectable circulating tumor DNA in their blood. #IMvigor011 #liquidbiopsy #ESMO NEJM.org
https://www.nature.com/articles/d41591-025-00065-1
https://www.nature.com/articles/d41591-025-00065-1
Liquid biopsy-guided adjuvant therapy in bladder cancer
Adjuvant atezolizumab improved survival outcomes in patients with muscle-invasive bladder cancer who had no radiographic disease but had detectable circulating tumor DNA in their blood.
www.nature.com
November 14, 2025 at 8:30 PM
⭐Research highlight: #Adjuvant #atezolizumab improved survival outcomes in patients with muscle-invasive #bladdercancer who had no radiographic disease but had detectable circulating tumor DNA in their blood. #IMvigor011 #liquidbiopsy #ESMO NEJM.org
https://www.nature.com/articles/d41591-025-00065-1
https://www.nature.com/articles/d41591-025-00065-1
In a follow up study presenting 96 week results, cabotegravir and rilpivirine long-acting therapy is still non-inferior to oral therapy for HIV, had acceptable safety and tolerability profiles and resulted in durable virologic suppression. https://www.nature.com/articles/s41591-025-04041-7
November 14, 2025 at 1:00 PM
In a follow up study presenting 96 week results, cabotegravir and rilpivirine long-acting therapy is still non-inferior to oral therapy for HIV, had acceptable safety and tolerability profiles and resulted in durable virologic suppression. https://www.nature.com/articles/s41591-025-04041-7
In a meta-analysis of 48 trials of chronic kidney disease progression, reduction in the 6-month urinary albumin:creatinine ratio was associated with lower hazard ratios of established kidney disease endpoints, supporting its use in clinical trials. https://www.nature.com/articles/s41591-025-04057-z
November 13, 2025 at 1:30 PM
In a meta-analysis of 48 trials of chronic kidney disease progression, reduction in the 6-month urinary albumin:creatinine ratio was associated with lower hazard ratios of established kidney disease endpoints, supporting its use in clinical trials. https://www.nature.com/articles/s41591-025-04057-z
Research doesn’t always ‘speak for itself’; uptake of science into #publichealth policy requires active engagement between researchers & policymakers. Prof. J. Jaime Miranda & colleagues offer tangible recommendations to help bridge this gap.
https://www.nature.com/articles/s41591-025-04015-9
https://www.nature.com/articles/s41591-025-04015-9
November 10, 2025 at 8:30 PM
Research doesn’t always ‘speak for itself’; uptake of science into #publichealth policy requires active engagement between researchers & policymakers. Prof. J. Jaime Miranda & colleagues offer tangible recommendations to help bridge this gap.
https://www.nature.com/articles/s41591-025-04015-9
https://www.nature.com/articles/s41591-025-04015-9
In a meta-analysis of 48 trials of chronic kidney disease progression, reduction in the 6-month urinary albumin:creatinine ratio was associated with lower hazard ratios of established kidney disease endpoints, supporting its use in clinical trials. https://www.nature.com/articles/s41591-025-04057-z
A meta-analysis of albuminuria as a surrogate endpoint for kidney failure - Nature Medicine
In a meta-analysis of 48 randomized trials of chronic kidney disease progression, reduction in the 6-month urinary albumin:creatinine ratio was associated with lower hazard ratios of established kidney disease endpoints, supporting the use of albuminuria change as a surrogate endpoint in clinical trials for chronic kidney disease.
www.nature.com
November 7, 2025 at 1:30 PM
In a meta-analysis of 48 trials of chronic kidney disease progression, reduction in the 6-month urinary albumin:creatinine ratio was associated with lower hazard ratios of established kidney disease endpoints, supporting its use in clinical trials. https://www.nature.com/articles/s41591-025-04057-z
Pretrained using 335,645 whole-slide images, a foundation model is developed to provide representations for slide- and patient-level tasks. It is capable of performing clinical tasks even in data-scarce scenarios, such as rare cancer diagnosis. https://www.nature.com/articles/s41591-025-03982-3
November 6, 2025 at 7:15 PM
Pretrained using 335,645 whole-slide images, a foundation model is developed to provide representations for slide- and patient-level tasks. It is capable of performing clinical tasks even in data-scarce scenarios, such as rare cancer diagnosis. https://www.nature.com/articles/s41591-025-03982-3
News & Views: A study expands the utility of gold-standard models to assess risks linked to consuming raw milk and cheese contaminated with #influenzaA — marking an important step toward better risk assessments in #publichealth.
https://www.nature.com/articles/s41591-025-04020-y
https://www.nature.com/articles/s41591-025-04020-y
Better models mean better risk assessment for influenza A infection - Nature Medicine
A new study expands the utility of the gold-standard ferret model to assess the risks that are associated with consuming raw milk and cheese contaminated with influenza A virus — marking an important step toward improving risk assessments in public health.
www.nature.com
November 6, 2025 at 5:03 PM
News & Views: A study expands the utility of gold-standard models to assess risks linked to consuming raw milk and cheese contaminated with #influenzaA — marking an important step toward better risk assessments in #publichealth.
https://www.nature.com/articles/s41591-025-04020-y
https://www.nature.com/articles/s41591-025-04020-y
In a follow up study presenting 96 week results, cabotegravir and rilpivirine long-acting therapy is still non-inferior to oral therapy for HIV, had acceptable safety profiles and resulted in durable virologic suppression. https://www.nature.com/articles/s41591-025-04041-7
Cabotegravir and rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trial - Nature Medicine
In this follow-up study presenting results at 96 weeks, cabotegravir and rilpivirine long-acting therapy remained noninferior to oral therapy, had acceptable safety and tolerability profiles, and resulted in durable virologic suppression, further supporting its consideration for African treatment programs.
www.nature.com
November 6, 2025 at 12:00 PM
In a follow up study presenting 96 week results, cabotegravir and rilpivirine long-acting therapy is still non-inferior to oral therapy for HIV, had acceptable safety profiles and resulted in durable virologic suppression. https://www.nature.com/articles/s41591-025-04041-7
In cognitively normal older adults at risk for Alzheimer’s dementia, physical inactivity was associated with faster tau protein buildup and cognitive decline https://www.nature.com/articles/s41591-025-03955-6 @WendyYau01 @HarvardAging @MGHNeurology
November 5, 2025 at 6:20 PM
In cognitively normal older adults at risk for Alzheimer’s dementia, physical inactivity was associated with faster tau protein buildup and cognitive decline https://www.nature.com/articles/s41591-025-03955-6 @WendyYau01 @HarvardAging @MGHNeurology
The first-in-human trial of AB-1002 suggests a cautious return of #cardiac #genetherapy after earlier setbacks, with a new target, dose optimization & improved vector design shaping future directions.
News & Views from Oliver Müller & colleagues
https://www.nature.com/articles/s41591-025-04002-0
News & Views from Oliver Müller & colleagues
https://www.nature.com/articles/s41591-025-04002-0
Cardiac gene therapy makes a comeback - Nature Medicine
The first-in-human trial of AAV2i8-I1c (AB-1002) — an adenovirus vector that targets a protein phosphatase inhibitor to cardiac muscle — suggests a cautious return of cardiac gene therapy after earlier setbacks, with a new target, dose optimization and improved vector design shaping future directions.
www.nature.com
October 27, 2025 at 11:01 AM
The first-in-human trial of AB-1002 suggests a cautious return of #cardiac #genetherapy after earlier setbacks, with a new target, dose optimization & improved vector design shaping future directions.
News & Views from Oliver Müller & colleagues
https://www.nature.com/articles/s41591-025-04002-0
News & Views from Oliver Müller & colleagues
https://www.nature.com/articles/s41591-025-04002-0
⭐Research highlight: Creativity enhances #brainhealth by improving connectivity in age-vulnerable regions, highlighting the importance of supporting creative activities in public health strategies.
Nature Communications
https://www.nature.com/articles/d41591-025-00063-3
Nature Communications
https://www.nature.com/articles/d41591-025-00063-3
Creativity keeps the brain young
A study shows that creativity enhances brain health by improving connectivity in age-vulnerable regions, highlighting the importance of supporting creative activities in public health strategies.
www.nature.com
October 24, 2025 at 7:01 PM
⭐Research highlight: Creativity enhances #brainhealth by improving connectivity in age-vulnerable regions, highlighting the importance of supporting creative activities in public health strategies.
Nature Communications
https://www.nature.com/articles/d41591-025-00063-3
Nature Communications
https://www.nature.com/articles/d41591-025-00063-3
⭐Research highlight: Baby wraps treated with the insecticide permethrin reduced the incidence of #malaria in infants by 66%, according to a randomized controlled trial in Uganda. @NEJM
https://www.nature.com/articles/d41591-025-00061-5
https://www.nature.com/articles/d41591-025-00061-5
A simple strategy to cut malaria infection rates in babies
Baby wraps treated with the insecticide permethrin reduced the incidence of malaria in infants by 66%, according to a randomized controlled trial in Uganda.
www.nature.com
October 24, 2025 at 5:55 PM
⭐Research highlight: Baby wraps treated with the insecticide permethrin reduced the incidence of #malaria in infants by 66%, according to a randomized controlled trial in Uganda. @NEJM
https://www.nature.com/articles/d41591-025-00061-5
https://www.nature.com/articles/d41591-025-00061-5
Now at #ESMO25: In the phase 2/3 AGITG DYNAMIC-III trial, post-surgery ctDNA was prognostic but de-escalated chemotherapy in patients with ctDNA-negative stage III colon cancer did not meet non-inferiority for 3 year recurrence-free survival https://www.nature.com/articles/s41591-025-04030-w
October 20, 2025 at 2:02 PM
Now at #ESMO25: In the phase 2/3 AGITG DYNAMIC-III trial, post-surgery ctDNA was prognostic but de-escalated chemotherapy in patients with ctDNA-negative stage III colon cancer did not meet non-inferiority for 3 year recurrence-free survival https://www.nature.com/articles/s41591-025-04030-w
Now at #ESMO25: In patients with locally advanced or metastatic solid tumors, treatment with a first in class inhibitor of the Hippo-YAP-TEAD pathway was safe and led to encouraging clinical response rates in patients with mesothelioma https://www.nature.com/articles/s41591-025-04029-3
October 19, 2025 at 2:01 PM
Now at #ESMO25: In patients with locally advanced or metastatic solid tumors, treatment with a first in class inhibitor of the Hippo-YAP-TEAD pathway was safe and led to encouraging clinical response rates in patients with mesothelioma https://www.nature.com/articles/s41591-025-04029-3
Now at #ESMO25: In a phase 2 trial, first-line treatment of patients with advanced gastric cancer, GEJ cancer or esophageal adenocarcinoma with anti-TIGIT + anti-PD-1 + FOLFOX led to encouraging objective response rates and survival outcomes https://www.nature.com/articles/s41591-025-04022-w
October 18, 2025 at 9:00 AM
Now at #ESMO25: In a phase 2 trial, first-line treatment of patients with advanced gastric cancer, GEJ cancer or esophageal adenocarcinoma with anti-TIGIT + anti-PD-1 + FOLFOX led to encouraging objective response rates and survival outcomes https://www.nature.com/articles/s41591-025-04022-w
Now at #ESMO25: In the phase 2 IKF/AIO PHERFLOT trial, perioperative FLOT + anti-PD-1 + anti-HER2 led to a pathological complete response rate of 48.4% in patients with resectable HER2+ esophagogastric adenocarcinoma @JosephTintelnot https://www.nature.com/articles/s41591-025-03979-y
October 18, 2025 at 8:00 AM
Now at #ESMO25: In the phase 2 IKF/AIO PHERFLOT trial, perioperative FLOT + anti-PD-1 + anti-HER2 led to a pathological complete response rate of 48.4% in patients with resectable HER2+ esophagogastric adenocarcinoma @JosephTintelnot https://www.nature.com/articles/s41591-025-03979-y